In DepthDRUG DEVELOPMENT

After decades, progress against an ‘undruggable’ cancer target

See allHide authors and affiliations

Science  01 Nov 2019:
Vol. 366, Issue 6465, pp. 561
DOI: 10.1126/science.366.6465.561

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

Cancer researchers are making progress toward a goal that has eluded them for more than 30 years: shrinking tumors by shutting off a protein called KRAS that drives growth in many cancer types. A new type of drug aimed at KRAS made tumors disappear in mice and shrank tumors in lung cancer patients, two companies report in papers published this week. It's not yet clear whether the drugs will extend patients' lives, but the results are generating a wave of excitement. And one company, Amgen, reports an unexpected bonus: Its drug also appears to stimulate the immune system to attack tumors, suggesting it could be even more powerful if paired with widely available immunotherapy treatments.

View Full Text